PHARMASIMPLE - PHARMASIMPLE: Press release following unfounded rumors circulating on social networks and stock market forums - 09/19/2022 - 6:00 p.m.

PHARMASIMPLE – PHARMASIMPLE: Press release following unfounded rumors circulating on social networks and stock market forums – 09/19/2022 – 6:00 p.m.

Press release following unfounded rumors circulating on social networks and stock market forums

Houdeng-Goegnies (Belgium), September 19, 2022, 6 p.m. – Following false allegations, repeatedly posted and repeated on social networks and stock market forums ostensibly aimed at harming the group, worrying its investors and producing possibly an exaggerated downward pressure on its share price, Pharmasimple (ISIN Code: BE0974302342. Mnemonic: ALPHS) declares:

  • Pharmasimple formally denies being insolvent or filing for bankruptcy.
  • The CEO of Pharmasimple is still at the helm of the company and is currently pursuing an ambitious transformation strategy to build a powerful group for the distribution of pharmaceutical and parapharmaceutical products with a plan to buy 150 pharmacies in 5 years.
  • Pharmasimple has long-term financial support from Alpha Blue Ocean, a company specializing in flexible financing for listed companies with which a €200 million financing agreement was signed in April 2022 in the form of Bonds Convertible into Shares currently in drawing course.

Contrary to the messages underlying these destabilization maneuvers, the Pharmasimple group is accelerating its transformation towards the physical distribution of its products with the acquisition of pharmacies, particularly in Belgium. A total of 14 pharmacies have been signed, of which 8 are already integrated and 3 are in the process of being integrated next October. 3 new pharmacies are under negotiation. On the strength of its experience in supplying its internet platforms, the group will also make the necessary requests to obtain the Belgian pharmaceutical wholesaler’s license in order to be able to buy and store medicines at the best prices, allowing it to improve its margins.

Finally, Pharmasimple is in the process of finalizing the reorganization of its internet division, which will lead to the disposal or discontinuation of activities now deemed unprofitable and non-strategic and correlatively to the reduction of certain assets, costs and workforce. Thanks to this restructuring carried out and the rise in revenue and profits from the operation of pharmacies, Pharmasimple is confidently looking forward to a sustainable return to growth.

The Pharmasimple group, which has the confidence of institutional and private investors and professionals in the pharmaceutical world, is well aware of being the subject, in a tense economic context and while the financial markets are volatile, of an organized attempt to destabilization, which may have led to a disproportionate erosion of its market capitalization to less than 600 K€ today.

To protect its reputation, assets, employees and investors, Pharmasimple and its officers reserve the right to file a complaint against anyone who creates, repeats or amplifies such unfounded rumors.

Next publication: Results of 1er semester 2022: October 11, 2022 after scholarship.

About Pharmasimple: Pharmasimple, specializing in the online sale of parapharmaceutical products, is one of the main players in France. The company offers more than 120,000 references of cosmetic and dermo-cosmetic products, medical accessories and food supplements. In 2021, Pharmasimple achieved a turnover of €30 million. The Group aims to become one of the leaders in its sector in Europe. Pharmasimple benefits from the “Innovative Company” label awarded by Bpifrance. Pharmasimple shares are listed on the Euronext Growth market. ISIN code: BE0974302342. Mnemonic: ALPHS.

contacts:

.

Back to top